Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:727569.
doi: 10.1155/2015/727569. Epub 2015 Apr 5.

Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support-Results of a Prospective, Randomized, Comparative Study

Céline Pirard  1 , Ernest Loumaye  2 , Pascale Laurent  1 , Christine Wyns  1
Affiliations

Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support-Results of a Prospective, Randomized, Comparative Study

Céline Pirard et al. Int J Endocrinol. 2015.

Abstract

Background. The aim of this pilot study was to evaluate intranasal buserelin for luteal phase support and compare its efficacy with standard vaginal progesterone in IVF/ICSI antagonist cycles. Methods. This is a prospective, randomized, open, parallel group study. Forty patients underwent ovarian hyperstimulation with human menopausal gonadotropin under pituitary inhibition with gonadotropin-releasing hormone antagonist, while ovulation trigger and luteal support were achieved using intranasal GnRH agonist (group A). Twenty patients had their cycle downregulated with buserelin and stimulated with hMG, while ovulation trigger was achieved using 10,000 IU human chorionic gonadotropin with luteal support by intravaginal progesterone (group B). Results. No difference was observed in estradiol levels. Progesterone levels on day 5 were significantly lower in group A. However, significantly higher levels of luteinizing hormone were observed in group A during the entire luteal phase. Pregnancy rates (31.4% versus 22.2%), implantation rates (22% versus 15.4%), and clinical pregnancy rates (25.7% versus 16.7%) were not statistically different between groups, although a trend towards higher rates was observed in group A. No luteal phase lasting less than 10 days was recorded in either group. Conclusion. Intranasal administration of buserelin is effective for providing luteal phase support in IVF/ICSI antagonist protocols.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Randomization and allocation of patients to the two groups. In group A, ovulation was triggered with buserelin and the luteal phase was also supported by buserelin. In group B, ovulation was triggered with hCG and the luteal phase was supported with vaginal micronized progesterone.
Figure 2
Figure 2
Hormone levels during the luteal phase on D0 (day of ovulation trigger), D2, D5, D9, and D14. (a) Mean progesterone levels. (b) Mean estradiol levels. (c) Mean LH levels.
See this image and copyright information in PMC

References

    1. Macklon N. S., Fauser B. C. Impact of ovarian hyperstimulation on the luteal phase. Journal of reproduction and fertility. Supplement. 2000;55:101–108. - PubMed
    1. Pritts E. A., Atwood A. K. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Human Reproduction. 2002;17(9):2287–2299. doi: 10.1093/humrep/17.9.2287. - DOI - PubMed
    1. Smitz J., Camus M., Devroey P., Bollen N., Tournaye H., van Steirteghem A. C. The influence of inadvertent intranasal buserelin administration in early pregnancy. Human Reproduction. 1991;6(2):290–293. - PubMed
    1. van der Linden M., Buckingham K., Farquhar C., Kremer J. A., Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews. 2011;(10) doi: 10.1002/14651858.CD009154.pub2.CD009154 - DOI - PubMed
    1. Fujii S., Sato S., Fukui A., Kimura H., Kasai G., Saito Y. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Human Reproduction. 2001;16(8):1671–1675. doi: 10.1093/humrep/16.8.1671. - DOI - PubMed

LinkOut - more resources